非酒精性脂肪性肝炎与非肝硬化患者亚临床心肌功能障碍的相关性
在三级医院纳入308例患者(190例无NAFLD,118例有NAFLD),用18FDG-PET评估心肌葡萄糖摄取,用瞬态弹性成像和替代指标评估肝脂肪变和纤维化,超声心动图评估心脏结构和功能。结果显示肝脂肪变和纤维化与舒张性心脏功能障碍显著相关,此关联与心肌葡萄糖摄取改变有关。
要点
- NAFLD患者较无NAFLD者出现心脏重构改变,包括左心室质量指数、左心室舒张末期内径和左心房容积指数增加(均p<0.05)。
- 肝脂肪变与反映舒张功能障碍的左心室充盈压(E/e'比值)显著相关(趋势p<0.05)。
- 显著肝纤维化与舒张功能障碍及心肌葡萄糖摄取受损相关。
核心结论
- 肝脂肪变和肝纤维化与舒张性心脏功能障碍显著相关。
- 此关联与18FDG-PET评估的心肌葡萄糖摄取有关。
研究设计与样本
- 在三级医院开展的研究,共纳入308例患者,其中190例无NAFLD,118例有NAFLD。
- 采用18FDG-PET在空腹状态评估心肌葡萄糖摄取。
- 采用瞬态弹性成像(Fibroscan®)联合受控衰减参数及替代指标(脂肪肝指数和NAFLD纤维化评分)评估肝脂肪变和纤维化。
- 采用超声心动图检查心脏结构和功能。
主要发现
- 与无NAFLD者相比,NAFLD患者出现心脏重构改变,表现为左心室质量指数、左心室舒张末期内径和左心房容积指数增加(均p<0.05)。
- 肝脂肪变与左心室充盈压(E/e'比值)显著相关,反映舒张功能障碍(趋势p<0.05)。
- 无NAFLD者较NAFLD者更可能具有较高的心肌葡萄糖摄取。
- 显著肝纤维化与舒张功能障碍及心肌葡萄糖摄取受损相关。
- 多变量线性回归显示,E/e'比值与肝纤维化独立相关(标准化β=0.12至0.27;均p<0.05),与肝脂肪变的关联也显著(标准化β=0.10至0.15;除校正肥胖的模型外均p<0.05)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Non-alcoholic fatty liver disease (NAFLD) is associated with increased cardiovascular risk. Among categories of NAFLD, hepatic fibrosis is most likely to affect mortality. Myocardial function and its energy metabolism are tightly linked, which might be altered by an insulin resistant condition such as NAFLD. We investigated whether hepatic steatosis and fibrosis were associated with myocardial dysfunction relative to myocardial glucose uptake. METHODS: A total of 308 patients (190 without NAFLD, 118 with NAFLD) were studied in a tertiary care hospital. Myocardial glucose uptake was evaluated at fasted state using [18F]-fluorodeoxyglucose-positron emission tomography (18FDG-PET). Hepatic steatosis and fibrosis were assessed by transient liver elastography (Fibroscan®) with controlled attenuation parameter, which quantifies hepatic fat and by surrogate indices (fatty liver index and NAFLD fibrosis score). Cardiac structure and function were examined by echocardiogram. RESULTS: Compared to those without NAFLD, patients with NAFLD had alterations in cardiac remodeling, manifested by increased left ventricular mass index, left ventricular end-diastolic diameter, and left atrial volume index (all p <0.05). Hepatic steatosis was significantly associated with left ventricular filling pressure (E/e' ratio), which reflects diastolic dysfunction (p for trend <0.05). Those without NAFLD were more likely to have higher myocardial glucose uptake compared to those with NAFLD. Significant hepatic fibrosis was also correlated with diastolic dysfunction and impaired myocardial glucose uptake. Using multivariable linear regression, E/e' ratio was independently associated with hepatic fibrosis (standardized β = 0.12 to 0.27; all p <0.05). Association between hepatic steatosis and E/e' ratio was also significant (standardized β = 0.10 to 0.15; all p <0.05 excluding the model adjusted for adiposity). CONCLUSIONS: Hepatic steatosis and fibrosis are significantly associated with diastolic heart dysfunction. This association is linked with myocardial glucose uptake evaluated by 18FDG-PET. LAY SUMMARY: Non-alcoholic fatty liver disease is associated with an increased risk of cardiovascular disease. More severe forms of non-alcoholic fatty liver disease, where hepatic fibrosis occurs, are linked to increased mortality. In this study, we have shown that hepatic steatosis and fibrosis are associated with subclinical myocardial dysfunction. This association is linked to altered myocardial glucose uptake.
引用
- Lee YH, Kim KJ, Yoo ME, et al. Association of non-alcoholic steatohepatitis with subclinical myocardial dysfunction in non-cirrhotic patients. J Hepatol. 2017. PMID: 29175242. doi:10.1016/j.jhep.2017.11.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。